Monographs: Dosage forms: Specific monographs: Ciprofloxacin tablets (Ciprofloxacini compressi)2020-01
Category. Antibacterial, antituberculosis. Storage. Ciprofloxacin tablets should be kept in a well closed container, protected from light. Labelling. The designation of the container of Ciprofloxacin tablets should state that the active ingredient is Ciprofloxacin hydrochloride and the quantity should be indicated in terms of the equivalent amount of ciprofloxacin. Additional information. Strengths in the current WHO Model list of essential medicines (EML): 250 mg. Strengths in the current WHO EML for children: 250 mg. Requirements Comply with the monograph for Tablets. Definition. Ciprofloxacin tablets contain Ciprofloxacin hydrochloride. They contain not less than 90.0% and not more than 110.0% of the amount of ciprofloxacin (C17H18FN3O3) stated on the label. Identity test Either test A, B or C may be applied.
Dissolution. Carry out the test as described under 5.5 Dissolution test for solid oral dosage forms, using as the dissolution medium 900 ml of hydrochloric acid (~3.65 g/L) TS and rotating the paddle at 50 revolutions per minute. At 30 minutes, withdraw a sample of about 10 mL of the medium through an in-line filter. Allow the filtered sample to cool to room temperature. Dilute the solution with dissolution medium if necessary. Measure the absorbance (1.6) of a 1.0 cm layer of the sample at about 276 nm. At the same time, measure the absorbance of a suitably diluted solution of ciprofloxacin hydrochloride RS in hydrochloric acid (~ 3.65 g/L) TS using hydrochloric acid (~ 3.65 g/L) TS as a blank. For each of the tablets, calculate the total amount of ciprofloxacin (C17H18FN3O3), in the medium. Each mg of ciprofloxacin hydrochloride (C17H18FN3O3,HCl) corresponds to 0.901 mg of ciprofloxacin (C17H18FN3O3). Evaluate the results as described under 5.5 Dissolution test for solid oral dosage forms, Acceptance criteria. The amount of ciprofloxacin released is not less than 80% (Q) of the amount declared on the label. [Note from the Secretariat. It is intended to determine the absorptivity value of ciprofloxacin hydrochloride at a later stage. The value will then be included in the test description.] Related substances. Prepare fresh solutions, protected from light, and perform the test without delay. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using the conditions given under "Assay". Prepare the following solutions in mobile phase. For solution (1), transfer a quantity of the powdered tablets, nominally equivalent to 125.0 mg of ciprofloxacin, into a 250 mL volumetric flask, add about 180 ml, sonicate for 5 minutes, dilute to volume, mix and filter. For solution (2), dilute 1.0 mL of solution (1) to 100.0 mL. For solution (3), dilute 1.0 mL of solution (2) to 10.0 mL. For solution (4), dissolve 2.5 mg of ciprofloxacin hydrochloride for peak identification RS (containing the impurities B, C, D and E) and dilute to 5.0 mL. Inject 10 μL each of solution (1), (2), (3) and (4) and record the chromatograms for about 2.3 times the retention time of ciprofloxacin. Use the chromatogram obtained with solution (4) to identify the peaks due to impurities B, C and E. The impurities are eluted, if present, at the following relative retention with reference to ciprofloxacin (retention time about 9 minutes); impurity E about 0.4; impurity B about 0.6; impurity C about 0.7; impurity D about 1.2. The test is not valid unless, in the chromatogram obtained with solution (4), the resolution factor between the peaks due to impurity B and impurity C is at least 2.0. In the chromatogram obtained with solution (3), the signal-to-noise ratio of the peak due to ciprofloxacin is at least 20. In the chromatogram obtained with solution (1):
Assay. Prepare fresh solutions, protected from light and perform the test without delay. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using a stainless steel column (25 cm x 4.6 mm), packed with end-capped and base-deactivated particles of silica gel, the surface of which has been modified with chemically-bonded octadecylsilyl groups (5 μm). Prepare the following buffer solution. Carefully add 3.4 mL of phosphoric acid (~1440 g/L) TS to 1600 ml of water R and mix. Adjust the pH with triethylamine to a pH of 3.0 (+/- 0.1) and dilute to 2000 mL with water R. As the mobile phase, use a mixture of acetonitrile R and buffer solution (13:87 v/v). Operate with a flow rate of 1.5 mL per minute. As a detector, use an ultraviolet spectrophotometer set at a wavelength of 278 nm. Maintain the column temperature at 40 °C. Weigh and powder 20 tablets. For solution (1), transfer a quantity of the powdered tablets, nominally equivalent to 100.0 mg of ciprofloxacin, into a 500 mL volumetric flask, add about 400 mL of the mobile phase, shake for 30 minutes, dilute to volume, mix and filter. For solution (2), dissolve 40.0 mg of ciprofloxacin hydrochloride RS in mobile phase and dilute to 200.0 mL using the same solvent. Inject alternately 10 μL each of solution (1) and (2) and record the chromatograms for about 2.3 times the retention time of ciprofloxacin. Measure the areas of the peaks corresponding to ciprofloxacin obtained in the chromatograms of solutions (1) and (2) and calculate the percentage content of ciprofloxacin (C17H18FN3O 3) in the tablets, using the declared content of ciprofloxacin hydrochloride (C17H18FN3O3,HCl) ciprofloxacin hydrochloride RS. Each mg of ciprofloxacin hydrochloride (C17H18FN3O3,HCl) corresponds to 0.901 mg of ciprofloxacin (C17H18FN3O3). Impurities. The impurities limited by the requirements of this monograph include those listed in the monograph for Ciprofloxacin hydrochloride. |